Comparison of intravenous nitroglycerin and sodium nitroprusside in acute myocardial infarction.
Initial studies from our institution demonstrated beneficial anti-ischemic effects of short-term infusion of intravenous nitroglycerin in patients with acute myocardial infarction. At lower doses, nitroglycerin was shown to be principally a venodilator; at higher doses, a mixed venous and arterial dilating effect was demonstrated. The acute hemodynamic effects of nitroglycerin varied in the presence or absence of left ventricular failure; patients with the most severe degree of left ventricular dysfunction had the most beneficial hemodynamic effect. Similar differential effects have been demonstrated for nitroprusside in other studies. A comparison of the arterial vasodilating potency of nitroglycerin and nitroprusside in patients in whom acute hypertension develops following coronary artery bypass surgery revealed that equal lowering of arterial pressure and systemic vascular resistance could be demonstrated in 85 percent of the patients with comparable infusion rates. Review of previous clinical and laboratory studies in animals, in which the effects of nitroglycerin and nitroprusside were compared, in most cases revealed opposite effects on intercoronary collateral flow and, thereby, opposite effects on the severity of regional ischemia. Our recently completed randomized placebo-controlled clinical trial employing a 48-hour infusion of nitroglycerin demonstrated a higher incidence of significant improvement in abnormalities noted on scintigraphy when nitroglycerin treatment was initiated within 10 hours of the onset of symptoms. Beneficial effects of early nitroglycerin treatment have also been demonstrated in previous clinical trials. In similar studies, which utilized nitroprusside infusions in patients with acute myocardial infarction, some investigators found an increase in short-term mortality with early nitroprusside treatment whereas others found benefit. The uniformly favorable results of the clinical trials that utilized intravenous nitroglycerin, although not necessarily supporting its routine use in all patients, would support a preference for nitroglycerin over nitroprusside for the treatment of congestive heart failure and/or acute hypertension complicating acute myocardial infarction.
D000368:Aged; D002986:Clinical Trials as Topic; D003097:Collateral Circulation / Q000187:drug effects; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003326:Coronary Circulation / Q000187:drug effects; D005292:Ferricyanides / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007263:Infusions, Parenteral; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*; D009599:Nitroprusside / Q000008:administration & dosage / Q000627:therapeutic use*
D005292:Ferricyanides; D009599:Nitroprusside; D005996:Nitroglycerin